CAS: 6160-65-2; 1,1'-Thiocarbonyldiimidazole

相似化合物

84661-56-3 104619-51-4 530-62-1

上下游产品

CAS号463-71-8 硫光气 | CAS号18156-74-6 三甲基硅咪唑(TSIM) | CAS号288-32-4 咪唑 | CAS号3529-87-1 4-苯氧基苯基异硫氰酸酯 | CAS号3694-57-3 4-甲氧基苄基异硫氰酸酯 | CAS号149488-61-9 N-(5-chloropyri... | CAS号22943-93-7 1-chloro-4-(4-i... | CAS号184003-55-2 1-tert-butyl-4-... | CAS号19715-56-1 1-isothi°Cyanat... | CAS号21578-46-1 N-(2-氨基苯基)-N-苯基硫脲 | CAS号102-08-9 二苯基硫脲 | CAS号26328-58-5 1-Benzyl-4-isot... | CAS号2816-87-7 a-D-Glucofurano...

硫光气,三甲基硅咪唑 以 甲苯 作为反应溶剂,化学反应生成 N,N'-硫羰基二咪唑
参考文献:基于四甲基-Ttp的有机分子导体:由阴离子尺寸和形状调节的结构和电学性质
标题:基于四甲基-Ttp的有机分子导体:由阴离子尺寸和形状调节的结构和电学性质
摘要:成功合成了双稠合四硫富瓦烯的四甲基衍生物 2,5-Bis(4,5-Dimethyl-1,3-Dithiol-2-Ylidene)-1,3,4,6-Tetrathiapentalene (Tmttp).大多数由 Tmttp 组成的自由基阳离子盐在单晶上具有 σ Rt = 10 1至 10 2 S Cm-1的高电导率.tmttp 导体的阴离子形状和尺寸调节电性能.pf 6-和 Asf 6-盐表现出低至 10 K 的金属电导率,而 Reo 4-和 Aui 2-盐分别在 126 和 11 K 时显示出金属到绝缘体 (Mi) 的转变.(Tmttp) 2 X (X = Pf 6,Asf 6,Bf 4,和 Reo 4) 和 (Tmttp) 3 Aui 2的单晶 X 射线结构分析表明,供体堆积基序被归类为所谓的β型.(Tmttp) 2 X (X = Reo 4,Bf 4,Pf 6和asf
DOI:10.1021/acs.Inorgchem.1C04004

专利信息

专利号:US-2004018598-A1
优先权日:2000-05-30
标题 :Bio-intermediates for use in the chemical synthesis of polyketides
发明人：SANTI DANIEL; ASHLEY GARY; MYLES DAVID C
摘要:The present invention relates to compounds made by a subset of modules from one or more polyketide synthase (“PKSâ€?) genes that are used as starting material in the chemical synthesis of novel molecules, particularly naturally occurring polyketides or derivatives thereof. The biologically derived intermediates (“bio-intermediatesâ€?) generally represent particularly difficult compounds to synthesize using traditional chemical approaches due to one or more stereocenters. In one aspect of the invention, an intermediate in the synthesis of epothilone is provided that feeds into the synthetic protocol of Danishefsky and co-workers. In another aspect of the invention, intermediates in the synthesis of discodermolide are provided that feed into the synthetic protocol of Smith and co-workers. By taking advantage of the inherent stereochemical specificity of biological processes, the syntheses of key intermediates and thus the overall syntheses of compounds like epothilone and discodermolide are greaty simplified.

专利号:US-2008125587-A1
优先权日:2006-05-25
标 题 :Synthesis of triazole compounds that modulate HSP90 activity
发明人：CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
权利人:CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
摘要:The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: n n n n n n n n n n with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. n In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) n n n n n n n n n n with an oxidizing agent, thereby producing a compound of formula (IA). n The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: n n n n n n n n n n in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula:

专利号:US-12240835-B2
优先权日:2018-09-18
标题:Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity
发明人：ROMERO F ANTHONY; KIRSCHBERG THORSTEN A; HALCOMB RANDALL; XU YINGZI
权利人:TERNS PHARMACEUTICALS INC
摘要:Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.

专利号:US-8198465-B2
优先权日:2005-10-17
标 题 :3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
发明人：SEDELMEIER GOTTFRIED; GRIMLER DOMINIQUE; ACEMOGLU MURAT
权利人:SEDELMEIER GOTTFRIED; GRIMLER DOMINIQUE; ACEMOGLU MURAT; NOVARTIS AG
摘要:The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula II, n nor a salt thereof, and a compound of formula VIn n nor a salt thereof, wherein R 3 and R 4 as well as Act are as defined in the specification, and processes of manufacturing these.n n Additionally transformation of compounds (VI) with metallo organic compounds (VII) give rise to the new compounds (VIII) which are direct precursors for the preparation of Aliskiren.

专利号:US-7935837-B2
优先权日:2008-04-30
标 题:Process for synthesis of androstane 17-β carbothioic acid and relative compounds thereof
发明人：HSU NAI-HSUAN; PANG CHU-YI; WU CHIEN-JEN; HUANG CHI-JEN; HSU CHIA-JUNG; LEE PEIMIN
权利人:CORUM INC
摘要:A process for synthesis of androstane 17-β carbothioic acid is provided. The process includes mixing an androstane 17-β carboxylic acid and a coupling reagent, and adding an alkanethioic acid to form an androstane 17-β carbothioic acid, wherein the androstane 17-β carbothioic acid has the formula (I): n n n n n n n n n n n n wherein R 1 represents hydrogen or haloalkyl groups, R 2 represents C 1-8 linear alkyl groups, C 1-8 branched alkyl groups, C 1-6 unsaturated acyclic groups or aromatic groups, R 3 represents hydrogen or hydroxyl, R 4 represents hydrogen, bromine, chlorine or fluorine and R 5 represents hydrogen, bromine, chlorine or fluorine. The process is a one-pot reaction.

专利号:US-5506349-A
优先权日:1992-05-13
标 题 :Chemical synthesis of 2', 3'-dideoxycytidine
发明人：MATULIC-ADAMIC JASENKA
权利人:RIBOZYME PHARM INC
摘要:Method for synthesis of 2',3'-dideoxycytidine by providing 5'-silylated-2',3'-dideoxyuridine as an intermediate.